Serum levels of slCAM-1 and 5-S-cysteinyldopa as markers of melanoma progression
Serum levels of slCAM-1 and 5-S-cysteinyldopa as markers of melanoma progression
复制标题
slCAM-1 和 5-S-半胱氨酰多巴的血清水平作为黑色素瘤进展的标志物
作者：
S. Hirai;T. Kageshita;T. Kimura;M. Tsujisaki;K. Imai;K. Wakamatsu;S. Ito;Y. Ono
采用双决定簇免疫分析法和高效液相色谱法分别测定血清可溶性细胞间粘附分子-1（sICAM-1）和5-S-半胱氨酰多巴（5-S-CD）水平。分析了53例黑色素瘤患者（1期，12例患者; II期，11例; III期，19例; IV期，11例;样本总数，116例）和31例年龄和性别匹配的健康对照受试者。IV期患者的sICAM-1和5-S-CD水平均显著高于I、II和III期患者（sICAM-1;均P<0.001; 5-S-CD;均P<0.05）。血清5-S-CD水平仅在IV期患者中升高。sICAM-1水平随着疾病进展而逐渐升高。序贯性眼睑炎的检测显示，在大多数疾病进展的患者中，sICAM-1和5-S-CD水平均升高。然而，5- S-CD水平不升高，在那些患者的转移是无色素的。sICAM-1与5-S-CD水平呈显著正相关（R= 0.655，P< 0.001）。5-S-CD的血清水平可能是一个有用的参数，用于监测转移瘤是黑色素的患者的疾病的临床过程。血清中sICAM-1和5-S-CD水平的分析将极大地有助于监测黑素瘤患者的临床过程。
The serum levels of the soluble form of intercellular adhesion molecule-1 (slCAM-1) and 5-S-cysteinyldopa (5-S-CD) were determined by double determinant immunoassay and high-performance liquid chromatography, respectively. Fifty-three melanoma patients (stage 1, 12 patients; stage II, 11; stage III, 19; and stage IV, 11; total number of samples, 116) and 31 age- and sex-matched healthy control subjects were analysed. Both the slCAM-1 and 5-S-CD levels were significantly higher in stage IV patients than those in stage I, II and III patients (slCAM-1; all P<0.001; 5-S-CD; all P<0.05). The serum levels of 5-S-CD were elevated only in stage IV patients. slCAM-1 levels elevated gradually with disease progression. Testing of sequential bleedings showed that both slCAM-1 and 5-S-CD levels were elevated in most of the patients whose disease had progressed. However 5- S-CD levels were not elevated in those patients whose metastases were amelanotic. There was a statistically significant correlation between slCAM-1 and 5-S-CD levels (R=0.6 55, P< 0.001). Serum levels of 5-S-CD may be a useful parameter for monitoring the clinical course of the disease in patients whose metastases are melanotic. Analysis of both slCAM-1 and 5-S-CD levels in serum will contribute greatly to monitoring the clinical course of melanoma patients.